Clinical trial / 2012
In a 24-week randomized trial, oral curcumin showed no clinical or biomarker efficacy in mild-to-moderate Alzheimer's disease.
Thirty-six individuals with mild-to-moderate Alzheimer's disease were randomized to receive placebo, 2 g/day, or 4 g/day of oral Curcumin C3 Complex for 24 weeks. Curcumin was generally well-tolerated, though 3 of 24 participants in the curcumin group withdrew due to gastrointestinal symptoms. Curcumin was linked to clinically insignificant lowered hematocrit and increased glucose levels. No differences between treatment groups were observed in clinical cognitive outcomes or biomarker efficacy measures, with low levels of native curcumin measured in plasma (7.32 ng/mL).
- Study type
- Randomized, double-blind, placebo-controlled trial
- Who was studied
- 36 persons with mild-to-moderate Alzheimer's disease (mean age of 30 completers: 73.5 years)
- What was measured
- Adverse events, clinical laboratory tests, ADAS-Cog score, NPI, ADCS-ADL, and plasma/CSF biomarkers (Aβ, tau, F2-isoprostanes)
THE PAPER
Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study.
Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gylys KH, Badmaev V, Heath DD, Apostolova LG, Porter V, Vanek Z, Marshall GA, Hellemann G, Sugar C, Masterman DL, Montine TJ, Cummings JL, Cole GM. Alzheimers Res Ther, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.